Amoy Diagnostics Co., Ltd.

SZSE:300685 Rapport sur les actions

Capitalisation boursière : CN¥9.9b

Amoy Diagnostics Résultats passés

Passé contrôle des critères 5/6

Amoy Diagnostics has been growing earnings at an average annual rate of 15.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 13.2% per year. Amoy Diagnostics's return on equity is 17.4%, and it has net margins of 26.6%.

Informations clés

15.2%

Taux de croissance des bénéfices

15.1%

Taux de croissance du BPA

Biotechs Croissance de l'industrie11.3%
Taux de croissance des recettes13.2%
Rendement des fonds propres17.4%
Marge nette26.6%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Sep 18
Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23
Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27
Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24
Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18
Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02
What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01
Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Ventilation des recettes et des dépenses

Comment Amoy Diagnostics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

SZSE:300685 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 241,184315426217
30 Jun 241,128279424218
31 Mar 241,082268402215
31 Dec 231,044261390203
30 Sep 23951213383204
30 Jun 23908301378189
31 Mar 23831267364173
01 Jan 23842264367175
30 Sep 22871287395168
30 Jun 22911218390166
31 Mar 22949250388162
01 Jan 22917240374156
30 Sep 21890231373138
30 Jun 21844211364130
31 Mar 21811198356127
31 Dec 20728180339115
30 Sep 20650153308115
30 Jun 20595138292106
31 Mar 2055012928496
31 Dec 1957813529494
30 Sep 1954114026587
30 Jun 1950213524186
31 Mar 1946913421585
31 Dec 1843912720178
30 Sep 1839812218669
30 Jun 1838412015684
31 Mar 1835710316164
31 Dec 173309415751
30 Sep 173158216339
30 Jun 17288781930
31 Mar 17258671800
31 Dec 16253671810
30 Jun 16220421680
31 Mar 16198321570
31 Dec 15177211470
31 Dec 1410719820
31 Dec 137422520

Des revenus de qualité: 300685 has high quality earnings.

Augmentation de la marge bénéficiaire: 300685's current net profit margins (26.6%) are higher than last year (22.4%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 300685's earnings have grown by 15.2% per year over the past 5 years.

Accélération de la croissance: 300685's earnings growth over the past year (47.7%) exceeds its 5-year average (15.2% per year).

Bénéfices par rapport au secteur d'activité: 300685 earnings growth over the past year (47.7%) exceeded the Biotechs industry 0.08%.

Rendement des fonds propres

ROE élevé: 300685's Return on Equity (17.4%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y